US Biobanks Market Size Likely to Grow at a CAGR of 6.4% By 2035

The market size of the global soft tissue repair is estimated to be USD 17.6 billion in 2025, and it is estimated that such a market size will rise to USD 18.1 billion in 2026, and to around USD 26.5 billion in 2035, at an annual CAGR of 6.4% between the years 2026 and 2035.

US biobanks Market Revenue and Trends

It is projected that the US biobanks market will be in a strong boost in 2026-2035 due to the increasing demand of quality biological samples to aid in biomedical research, precision medicine, drug development, and clinical trials. The US has a broad assortment of biospecimen types stored and processed by biobanks such as blood, tissue, DNA, RNA, and cell lines that are utilized by academic institutions, pharmaceutical companies, and research organizations.

The expansion in the market revenue is also backed up by the augmented federal support to life sciences research, the broadening of genomics and oncology research, and the increased use of personalized and precision medicine methods. The high concentration of research universities, pharmaceutical enterprises, and contract research organizations (CROs) has kept the US as a world leader in the biobanking practices.

What are the Factors That Have a Significant Contribution to the Growth of the US biobanks market?

This trend in the US biobanks market is mainly motivated by the rising clinical research and large-scale population studies undertakings with the intention to discover the impact of genetics, environment, and lifestyle on disease. The increasing number of chronic diseases including cancer, cardiovascular diseases and neurological disorders has further increased the requirement of long term, well annotated biological sample repositories.

Genomics, proteomics and research based on biomarkers are rapidly growing in the US, especially oncology and rare disease research. These studies are based on the use of high-quality, standardized biospecimens, thus causing the continued need to be served with high-quality biobanking infrastructure and services in research institutions and biopharmaceutical industries.

The biobanks market is being influenced by technological advancements, which are becoming critical. The use of automated sample handling systems, enhanced cryopreservation systems, digital inventory management, and AI-enabled data integration has enhanced sample integrity, traceability and scalability. Such trends are raising modernization of the available biobanks and the creation of new specialized biorepositories in the US.

Segment Insight

By Sample Type

The largest market share of the US biobanks market is represented by human tissue samples as of 2025 because it is a vital tool of researching diseases, developing drugs, and translational medicine. These samples allow analysis of the disease progression in detail, identification of biomarkers, and response to treatment, and the development of standardized collection, long-term cryopreservation, and ethical consent schemes have substantially enhanced the utility and stability of these samples (which are broadly considered by researchers as being crucial to clinically relevant and high-value biomedical research).

By Application

The US biobanks market as of 2025 had the most prevalent application share attributed to genomics and precision medicine due to the increased attention to personalized treatment and genetic-based disease-level knowledge. Large-scale sequencing, biomarker discovery and population health studies rely on biobanked samples, which innovations in high-throughput sequencing, data integration, and AI-driven analytics have increased in research value (including making biobanks a foundational resource to precision-guided clinical and therapeutic development).

By End Use

Pharmaceutical and biotechnology firms constituted the most dominant end-use market of the US biobanks market by 2025 due to the high dependency of their companies on high-quality biospecimens in drug discovery, clinical trials, and regulatory filings. These groups use biobanks to speed up validation of targets and minimize risks of development, and collaborations with academic and public biorepositories have increased access to diverse sample collections (biobanks are being viewed as scalable and economical sources of R&D pipelines).

Report Scope

Recent Developments

• In December 2024, Thermo Fisher Scientific enhanced its biobanking automation offerings, which enabled sample processing on large-scale genomics initiatives with high throughput.

List of the prominent players in the US Biobanks Market:

• Thermo Fisher Scientific

• BioIVT

• Discovery Life Sciences

• Charles River Laboratories

• STEMCELL Technologies

• Promega Corporation

• Lonza Group

• Tecan Group

• QIAGEN

• PerkinElmer

• Merck KGaA (MilliporeSigma)

• Bio-Techne

• Sanofi (Research Biobanking Units)

• Roche Diagnostics

• Others

The US Biobanks Market is segmented as follows:

By Sample Type

• Human Tissues

• Blood & Derivatives

• Nucleic Acids

• Cell Lines

• Biofluids

By Application

• Genomics & Precision Medicine

• Drug Discovery & Development

• Oncology Research

• Regenerative Medicine

• Infectious Disease Research

• Others

By End Use

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Research Organizations

• Others